Atherosclerosis

Clinical Trial Finder

Many patients with atherosclerosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Determining the Relationship Between the Atherosclerosis and Periodontopathogenic Microorganisms

Conditions:   Atherosclerosis;   Chronic Periodontitis
Intervention:   Procedure: Non-surgical periodontal treatment
Sponsor:   Izmir Katip Celebi University
Completed - verified November 2016

Vorapaxar and Lower Extremity Bypass Grafts

Condition:   Peripheral Artery Disease
Interventions:   Drug: Vorapaxar;   Drug: Placebos
Sponsors:   Vanderbilt University;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified November 2016

Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly

Conditions:   Cognitive Decline;   Stroke
Intervention:  
Sponsor:   University Hospital, Lille
Not yet recruiting - verified November 2016

Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project

Conditions:   Cardiovascular Diseases;   Diabetes Mellitus;   Hypertension;   Dyslipidemias;   Overweight and Obesity
Intervention:   Behavioral: The Complete Health Improvement Program
Sponsors:   Ohio University;   Touro University
Recruiting - verified November 2016

Household Air Pollution and Health: A Multi-country LPG Intervention Trial

Condition:   Infant, Low Birth Weight
Intervention:   Other: Liquefied petroleum gas (LPG) cookstove
Sponsors:   Emory University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified November 2016

First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries

Condition:   Patients With Peripheral Artery Disease in the SFA or PA
Intervention:   Device: SELUTION DCB (sirolimus coated balloon)
Sponsor:   M.A. Med Alliance S.A.
Recruiting - verified December 2016

Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D

Condition:   Peripheral Arterial Disease
Intervention:   Device: BioMimics 3D Stent
Sponsor:   Veryan Medical Ltd.
Recruiting - verified November 2016

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Condition:   Migraine, With or Without Aura
Interventions:   Drug: Ubrogepant;   Drug: Placebo-matching Ubrogepant
Sponsor:   Allergan
Recruiting - verified December 2016

Folinic Acid: Supplementation and Therapy

Conditions:   HIV Infection;   HCV Coinfection
Interventions:   Drug: Folinic Acid;   Drug: Placebo
Sponsors:   Hospital de Clinicas de Porto Alegre;   Universidade Federal de Santa Maria
Completed - verified September 2016

A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes

Condition:   Ischemic Stroke
Intervention:   Drug: TF0023
Sponsor:   Techfields Inc
Recruiting - verified November 2016

Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

Conditions:   Angioplasty, Balloon;   Catheterization, Peripheral;   Popliteal Artery;   Femoral Artery
Interventions:   Device: IN.PACT drug coated balloon;   Device: Lutonix drug coated balloon
Sponsor:   Seung-Whan Lee, M.D., Ph.D.
Recruiting - verified November 2016

Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease

Condition:   Peripheral Arterial Disease
Interventions:   Other: Text Messages;   Other: Phone Calls;   Other: Handout
Sponsors:   University of Kansas Medical Center;   National Institute on Aging (NIA)
Active, not recruiting - verified November 2016

Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D)

Condition:   Atherosclerosis of the Peripheral Arteries
Interventions:   Procedure: Hybrid Intervention;   Procedure: Aorta femoral Bypass
Sponsor:   Meshalkin Research Institute of Pathology of Circulation
Active, not recruiting - verified November 2016

In-Stent Restenosis Post-Approval Study

Conditions:   Peripheral Artery Disease;   Vascular Disease
Intervention:   Device: Gore VIABAHN Endoprosthesis
Sponsor:   W.L.Gore & Associates
Enrolling by invitation - verified December 2016

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Met DR;   Drug: Met IR;   Drug: Placebo
Sponsor:   Elcelyx Therapeutics, Inc.
Completed - verified November 2016

Standard Versus PICO Dressings in Lower-Extremity Bypass Patients

Conditions:   Of Bypass Graft of the Extremities;   Peripheral Arterial Disease;   Vascular Diseases;   Cardiovascular Diseases
Interventions:   Device: PICO Single-Use Negative Pressure Dressings;   Other: Sterile Gauze Dressings
Sponsors:   Boston Medical Center;   Smith & Nephew, Inc.
Recruiting - verified November 2016

Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access

Conditions:   Peripheral Arterial Disease;   Peripheral Vascular Diseases;   Critical Limb Ischemia
Intervention:   Device: Bone marrow concentration device
Sponsor:   Biomet, Inc.
Available - verified June 2016

Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System

Condition:   Peripheral Arterial Disease
Intervention:   Device: BioMimics 3D Stent System
Sponsors:   Veryan Medical Ltd.;   ClinLogix. LLC;   Yale Cardiovascular Research Group;   Massachusetts General Hospital
Active, not recruiting - verified November 2016

Changes in Ischemia and Angina Over 1 Year Among ISCHEMIA Trial Screen Failures With no Obstructive CAD on Coronary CT Angiography

Conditions:   Microvascular Angina;   Angina Pectoris
Interventions:   Other: Quality of Life assessment;   Procedure: Stress imaging
Sponsors:   New York University School of Medicine;   Duke Clinical Research Institute;   Massachusetts General Hospital
Recruiting - verified December 2016

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Condition:   Coronary Artery Disease
Interventions:   Drug: Cilostazol;   Drug: Aspirin
Sponsor:   Seoul National University Bundang Hospital
Completed - verified November 2016

Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease.

Conditions:   Type 2 Diabetes;   Cardiovascular Diseases
Intervention:   Dietary Supplement: Omega-3 PUFA
Sponsors:   Jagiellonian University;   National Science Centre, Poland
Completed - verified November 2016

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   Cleveland Clinic Coordinating Center for Clinical Research (C5R);   Quintiles, Inc.
Recruiting - verified November 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified December 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified December 2016

Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy

Condition:   Atherosclerosis
Interventions:   Drug: SB-480848 40 mg;   Drug: SB-480848 80 mg;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified December 2016

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Condition:   Peripheral Artery Disease
Interventions:   Drug: ACZ885;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed - verified November 2016

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Conditions:   Intermittent Claudication;   Peripheral Artery Disease
Interventions:   Biological: PLX-PAD Low dose;   Biological: PLX-PAD high doses;   Biological: Double Placebo;   Biological: high dose +Placebo
Sponsor:   Pluristem Ltd.
Recruiting - verified November 2016

Effects of Avocado When Added to a Meat Patty on Inflammation in Healthy Men

Condition:   Healthy Volunteers
Intervention:   Other: Avocado
Sponsor:   University of California, Los Angeles
Completed - verified November 2016

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

Condition:   Atherosclerosis
Intervention:   Drug: darapladib
Sponsor:   GlaxoSmithKline
Completed - verified November 2016

The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease

Condition:   Atherosclerosis
Intervention:   Dietary Supplement: Crossover of R-alpha lipoic acid and placebo
Sponsors:   Oregon State University;   Oregon Health and Science University;   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting - verified November 2016

Lipoic Acid and Prevention of Heart Disease

Condition:   Atherosclerosis
Interventions:   Dietary Supplement: R-alpha lipoic acid;   Dietary Supplement: Placebo
Sponsors:   Oregon State University;   Oregon Health and Science University;   National Center for Complementary and Integrative Health (NCCIH)
Active, not recruiting - verified November 2016

An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

Condition:   Atherosclerosis
Interventions:   Drug: rilapladib;   Drug: placebo;   Other: 18F Fluorodeoxylucose (FDG)-PET
Sponsor:   GlaxoSmithKline
Completed - verified November 2016

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Condition:   Atherosclerosis
Intervention:   Drug: Darapladib (SB480848)
Sponsor:   GlaxoSmithKline
Completed - verified December 2016

A Study To Determine The Effect Of SB-480848 On Asthma

Condition:   Atherosclerosis
Intervention:   Drug: SB 480848, tablets
Sponsor:   GlaxoSmithKline
Completed - verified December 2016

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Peripheral Artery Disease
Intervention:   Procedure: MRI
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2016

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2016

Study of Clinical Features and Genetics of Hyperimmunoglobulin E Recurrent Infection

Condition:   Job's Syndrome
Intervention:  
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Albert Einstein College of Medicine of Yeshiva University
Recruiting - verified November 2016

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Conditions:   Atherosclerosis;   Cardiovascular Diseases;   Hypercholesterolemia;   Hypertension;   Diabetes Mellitus, Type 2;   Diabetes Mellitus;   Coronary Disease
Interventions:   Drug: Anti-hyperglycemic Agents;   Drug: Anti-hypertensive Agents;   Drug: Blinded fenofibrate or placebo plus simvastatin
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute on Aging (NIA);   National Eye Institute (NEI);   Centers for Disease Control and Prevention
Completed - verified November 2014